PFIZER, INC.

(PFE)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Pfizer-BioNTech, Moderna COVID-19 Jabs Shown Safe For Women Undergoing IVF in Study

01/26/2022 | 10:44pm EDT


© MT Newswires 2022
Stocks mentioned in the article
ChangeLast1st jan.
BIONTECH SE 6.88% 167.87 Delayed Quote.-34.88%
MODERNA, INC. 4.12% 143.38 Delayed Quote.-43.55%
PFIZER, INC. 0.50% 50.65 Delayed Quote.-14.23%
All news about PFIZER, INC.
05/19US Health Agency Approves Pfizer-BioNTech's COVID-19 Booster Jab For Children
MT
05/19CDC urges Pfizer booster for children ages 5 to 11
AQ
05/19EU health regulator backs using AstraZeneca COVID shot as booster
RE
05/19Thinking about trading options or stock in Tesla, Microsoft, Walt Disney, NVIDIA, or Pf..
PR
05/19PFIZER INC : Berenberg sticks Neutral
MD
05/18FDA Expands Eligibility for Pfizer-BioNTech COVID-19 Vaccine Booster Dose to Children 5..
AQ
05/18From storage to transport, hurdles to getting COVID vaccine to N.Koreans
RE
05/18China Junshi's potential COVID drug shows promise in small trial
RE
05/17BioNTech SE and Pfizer Inc. Announces the U.S. Food and Drug Administration Expands Eme..
CI
05/17DXC Technology Appoints Mike Salvino as Chairman, Succeeding Ian Read
MT
More news
Analyst Recommendations on PFIZER, INC.
More recommendations
Financials (USD)
Sales 2022 104 B - -
Net income 2022 35 662 M - -
Net cash 2022 10 478 M - -
P/E ratio 2022 8,45x
Yield 2022 3,20%
Capitalization 284 B 284 B -
EV / Sales 2022 2,63x
EV / Sales 2023 3,45x
Nbr of Employees 79 000
Free-Float 58,2%
Chart PFIZER, INC.
Duration : Period :
Pfizer, Inc. Technical Analysis Chart | PFE | US7170811035 | MarketScreener
Technical analysis trends PFIZER, INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Last Close Price 50,65 $
Average target price 57,79 $
Spread / Average Target 14,1%
EPS Revisions
Managers and Directors
Albert Bourla Chairman, Chief Executive & Operating Officer
David M. Denton Chief Financial Officer & Executive Vice President
Mikael Dolsten Executive VP, President-Research & Development
Lidia L. Fonseca Executive VP, Chief Digital & Technology Officer
Aida Habtezion Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
PFIZER, INC.-14.23%284 192
JOHNSON & JOHNSON2.59%461 811
ABBVIE INC.12.05%269 361
ELI LILLY AND COMPANY3.64%265 718
ROCHE HOLDING AG-15.26%264 329
NOVO NORDISK A/S1.07%238 091